LONDON-- GlaxoSmithKline PLC (GSK.LN) said a review of data from a phase III trial of losmapimod for heart treatment "did not indicate efficacy against the primary endpoint and did not support investment in the larger part B of the study as currently designed."

GSK's also said its Advair Diskus achieved its primary endpoint in a safety study of patients with asthma and that its shingles treatment Shingrix demonstrated "90% efficacy against shingles in people 70 years of age and over" in a Phase III trial.

Shares at 1116 GMT, down 3 pence, or 0.2%, at 1,366 pence valuing the company at GBP66.5 billion.

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

October 27, 2015 07:32 ET (11:32 GMT)

Copyright (c) 2015 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Gsk Charts.